Page 1

INOVIO POWERING DNA MEDICINES ™ NEWS RELEASE INOVIO Reports Third Quarter 2021 Financial Results 11/9/2021 INOVIO receives U.S. FDA authorization to proceed with INNOVATE Phase 3 segment for its COVID - 19 vaccine candidate , INO - 4800 , in the U.S. INOVIO has regulatory authorization for global Phase 3 trial for INO - 4800 in seven countries , including most recently announced Thailand ; Dosing for INNOVATE Phase 3 underway INO - 4800 is one of two vaccine candidates initially selected for WHO's Phase 3 Solidarity Trial Vaccines Investor Call Today at 4:30 PM ET PLYMOUTH MEETING , Pa . , Nov. 9 , 2021 / PRNewswire / -- INOVIO ( NASDAQ : INO ) , a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer , and HPV - associated diseases , today reported financial results for the quarter ended September 30 , 2021. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update . The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx . Dr. J. Joseph Kim , President and CEO of INOVIO , said , " This morning , INOVIO announced that the U.S. Food and Drug Administration ( FDA ) provided authorization to proceed for INOVIO'S INNOVATE Phase 3 segment for its COVID - 19 vaccine candidate , INO - 4800 , in the U.S. We're pleased to have the opportunity for U.S. clinical trial participants to potentially contribute to the enrollment in our INNOVATE Phase 3 segment . Today's U.S. announcement builds on our intensive global efforts in India , Brazil , Philippines , Mexico , Colombia , and Thailand where we have received authorizations to date . " With much of the world still requiring broader access to vaccines , INO - 4800 is particularly well - positioned to address global vaccine needs , having been shown , in clinical trials to - date , to be well - tolerated and to generate balanced immune responses which comprise both T and B cell engagement . In addition , INO - 4800 has demonstrated a favorable thermostability profile that could facilitate global distribution . I am pleased to share that the dosing for INNOVATE Phase 3 segment is underway and we aim to have interim efficacy data in the first half 2022. " 1